Amy Kramer

1.3k total citations
11 papers, 1.0k citations indexed

About

Amy Kramer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amy Kramer has authored 11 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amy Kramer's work include Melanoma and MAPK Pathways (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cutaneous Melanoma Detection and Management (3 papers). Amy Kramer is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cutaneous Melanoma Detection and Management (3 papers). Amy Kramer collaborates with scholars based in United States, France and Italy. Amy Kramer's co-authors include Peter J. O’Dwyer, Keith T. Flaherty, Maryann Gallagher, Andrea B. Troxel, Ravi K. Amaravadi, Katherine L. Nathanson, Patricia Sullivan, Richard D. Huhn, David L. Bajor and Scott Antonia and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Infectious Diseases.

In The Last Decade

Amy Kramer

11 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Kramer United States 9 454 403 402 245 98 11 1.0k
Stanley Frankel United States 13 424 0.9× 514 1.3× 196 0.5× 90 0.4× 49 0.5× 24 1.2k
Paul Vink Netherlands 12 172 0.4× 213 0.5× 726 1.8× 162 0.7× 71 0.7× 15 1.1k
James Strauss United States 14 394 0.9× 224 0.6× 370 0.9× 64 0.3× 92 0.9× 69 837
Annegret Van der Aa Belgium 17 482 1.1× 213 0.5× 495 1.2× 293 1.2× 71 0.7× 41 1.6k
A C Bloem Netherlands 18 363 0.8× 517 1.3× 532 1.3× 84 0.3× 50 0.5× 34 1.4k
Marco Palla Italy 14 576 1.3× 294 0.7× 293 0.7× 136 0.6× 60 0.6× 42 911
Virginia Cecconi Switzerland 12 357 0.8× 310 0.8× 680 1.7× 51 0.2× 63 0.6× 21 964
Iwona Hus Poland 18 458 1.0× 254 0.6× 710 1.8× 81 0.3× 40 0.4× 96 1.2k
Elena Shklovskaya Australia 21 529 1.2× 357 0.9× 1.1k 2.6× 113 0.5× 109 1.1× 33 1.5k
Sebastian Scholl Germany 21 206 0.5× 447 1.1× 351 0.9× 158 0.6× 81 0.8× 75 1.3k

Countries citing papers authored by Amy Kramer

Since Specialization
Citations

This map shows the geographic impact of Amy Kramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Kramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Kramer more than expected).

Fields of papers citing papers by Amy Kramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Kramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Kramer. The network helps show where Amy Kramer may publish in the future.

Co-authorship network of co-authors of Amy Kramer

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Kramer. A scholar is included among the top collaborators of Amy Kramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Kramer. Amy Kramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
2.
Rangwala, Reshma, Robert D. Leone, Yunyoung C Chang, et al.. (2014). Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 10(8). 1369–1379. 294 indexed citations
3.
Amaravadi, Ravi K., Lynn M. Schuchter, David F. McDermott, et al.. (2009). Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clinical Cancer Research. 15(24). 7711–7718. 89 indexed citations
4.
Vonderheide, Robert H., Keith T. Flaherty, Magi Khalil, et al.. (2007). Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody. Journal of Clinical Oncology. 25(7). 876–883. 416 indexed citations
5.
Amaravadi, Ravi K., David F. McDermott, Amy Kramer, et al.. (2007). Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. Journal of Clinical Oncology. 25(18_suppl). 8527–8527. 26 indexed citations
6.
Amaravadi, Ravi K., Lynn M. Schuchter, Amy Kramer, et al.. (2006). Preliminary results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. Journal of Clinical Oncology. 24(18_suppl). 8009–8009. 45 indexed citations
7.
Veronese, Maria Luisa, Keith T. Flaherty, Amy Kramer, et al.. (2005). Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 55(5). 497–501. 22 indexed citations
8.
Redlinger, Maryann, Amy Kramer, Keith T. Flaherty, et al.. (2004). A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer. Journal of Clinical Oncology. 22(14_suppl). 3767–3767. 10 indexed citations
9.
Redlinger, Maryann, Amy Kramer, K. T. Flaherty, et al.. (2004). A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer. Journal of Clinical Oncology. 22(14_suppl). 3767–3767. 4 indexed citations
10.
Bansal, Geetha P., Jeanine Hatfield, Frances Dunn, et al.. (1993). Candidate Recombinant Vaccine for Human B19 Parvovirus. The Journal of Infectious Diseases. 167(5). 1034–1044. 95 indexed citations
11.
Listgarten, Max A., et al.. (1989). Comparative longitudinal study of 2 methods of scheduling maintenance visits: 4‐year data. Journal Of Clinical Periodontology. 16(2). 105–115. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stanley Frankel Breakdown of academic impact, for papers by Paul Vink Breakdown of academic impact, for papers by James Strauss Breakdown of academic impact, for papers by Annegret Van der Aa Breakdown of academic impact, for papers by A C Bloem Breakdown of academic impact, for papers by Marco Palla Breakdown of academic impact, for papers by Virginia Cecconi Breakdown of academic impact, for papers by Iwona Hus Breakdown of academic impact, for papers by Elena Shklovskaya Breakdown of academic impact, for papers by Sebastian Scholl
Rankless by CCL
2026